Founder and CEO of Karyon Bio, USA, highlights role of AI and Bioinformatics in healthcare
As the CEO of Karyon Bio, Thirunagari introduced the company’s ground breaking Digital Liver initiative, an AI-powered approach to tackling Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Hyderabad: As AI continues to refine the blueprint of life, the fusion of Bioinformatics and Artificial intelligence would remain at the heart of personalized medicine, drug discovery, and genomic research, shaping the future of global healthcare, said Srinivas Thirunagari, Founder and CEO of Karyon Bio, California, USA.
During an invited talk entitled ‘AI, Bioinformatics and the future of Healthcare: Innovations and Opportunities’ organized by the Department of Computational and Systems Biology, School of Life Sciences, in association with the Federation of Asian Biotech Associations (FABA) here, he deliberated on the transformative role of Artificial Intelligence (AI) and Bioinformatics in revolutionizing modern healthcare.
He emphasized how AI-driven innovations are shaping precision medicine, diagnostics, and treatment strategies, enabling early disease detection and personalized healthcare solutions.
As the CEO of Karyon Bio, Thirunagari introduced the company’s ground breaking Digital Liver initiative, an AI-powered approach to tackling Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH).
By integrating multi-omics data, deep learning, and advanced imaging techniques, Karyon Bio is at the forefront of non-invasive diagnostics and biomarker discovery, paving the way for more effective liver disease management.
